查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985524

無血清培養基市場：按產品類型、無血清培養基類型、細胞類型、配方、應用和最終用戶分類－2026-2030年全球市場預測

Serum-Free Media Market by Product Type, Serum-Free Media Type, Cell Type, Formulation, Application, End User - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年無血清培養基市場價值為 25.1 億美元，預計到 2025 年將成長至 27.6 億美元，複合年成長率為 10.07%，到 2030 年將達到 44.7 億美元。

主要市場統計數據
基準年 2024 25.1億美元
預計年份：2025年 27.6億美元
預測年份 2030 44.7億美元
複合年成長率 (%) 10.07%

這篇富有洞察力的介紹將無血清培養基定位為可重複細胞培養、可擴展生物製程和更安全的生物製藥開發的基礎。

隨著科學進步、監管要求和商業性需求不斷重塑科研和生產環境中的細胞培養技術，無血清培養基的格局也迅速演變。無血清培養基已從小眾技術解決方案發展成為基礎技術，能夠降低變異性、減輕生物風險並簡化下游製程。相關人員優先考慮成分明確、性能可重複以及與可擴展生物製程流程的兼容性，以支援更先進的生物製藥、細胞和基因治療以及再生醫學應用。

科學進步、監管監督和細胞療法的產業化正在將無血清培養基轉變為策略性的生物程序推動因素。

在科學創新、細胞療法產業化以及監管機構對原料可追溯性日益重視的推動下，無血清培養基領域正經歷著一場變革。細胞株工程和系統生物學的進步推動了對特定細胞表現型定製製劑的需求，使得培養基的配方從標準化轉向能夠最佳化生產效率和關鍵品質屬性的客製化。同時，細胞和基因療法的產業化也增加了對能夠在大規模生產環境中穩定運行，並能滿足監管機構對成分一致且特性明確的原料的要求的培養基的需求。

評估關稅中斷對無血清培養基原料和物流對下游供應鏈和營運韌性的影響。

2025年公佈的關稅政策的累積影響，為原料和無血清配方產品的供應鏈帶來了新的複雜性。影響試劑、胺基酸、特殊生長因子和包裝組件的關稅措施，可能導致關鍵原料的接收成本增加和交貨前置作業時間延長。為應對此問題，採購和供應鏈團隊正在優先考慮庫存策略、替代採購管道和供應商認證活動，以確保供應的連續性，同時維持產品品質和合規性。

全面的細分洞察揭示了細胞類型、產品結構、培養基成分選擇、應用要求和最終用戶需求如何塑造培養基成分策略。

細分市場為解讀無血清培養基生態系中技術需求與商業性機會的交會點提供了一個系統性的觀點。基於細胞類型，區分哺乳動物細胞和非哺乳動物細胞對於配方設計至關重要，因為它們在營養利用效率、生長動力學和產品品質特性方面存在顯著差異。哺乳動物細胞，例如 CHO 細胞、HEK293 細胞、NS0 細胞和 Vero 細胞，在滲透壓、生長因子和添加劑方面表現出不同的需求，這些需求會影響細胞生產力和轉譯後修飾。非哺乳動物細胞，以昆蟲細胞和酵母細胞為代表，具有不同的代謝需求和耐受性，通常需要不同的緩衝液和碳源策略，同時兼顧成本效益。

決定全球部署模式、供應鏈策略和發展重點的區域趨勢和監管環境。

區域趨勢顯著影響無血清培養基在不同生態系的開發、生產與應用。在美洲，學術創新中心、合約研發生產力機構 (CDMO) 和大規模生物製藥生產設施之間的緊密合作，推動了對符合 GMP 標準且具備可擴展生產流程的製劑的需求。此外，該地區的管理體制和成熟的供應鏈網路也支持從實驗室到臨床實踐的快速轉化。

在無血清培養基生態系統中，塑造產品創新、夥伴關係和品質主導差異化的競爭和企業策略。

無血清培養基領域的競爭格局由那些兼具配方專業知識、法規知識和供應鏈能力的公司所主導。主要企業正投資研發特定應用培養基，推出針對高價值治療領域的產品，並拓展分析服務以支援客戶的合格評估。與合約研發生產機構 (CDMO) 和學術研究中心建立策略夥伴關係十分普遍，這有助於加速專業配方的檢驗和市場推廣進程。

為研發、供應鏈、監管和商業領域的領導者提供實用建議，以增強韌性、加速推廣應用並提高產品與市場的契合度。

為實現策略價值，產業領導者應採取一系列合作舉措，將研發、供應鏈和商業部門連結起來。首先，應優先投資分析平台和細胞特異性製劑科學，以加速開發週期並降低規模化生產過程中的風險。同樣重要的是製定靈活的生產策略，包括關鍵原料的雙重採購和區域生產方案，以減輕政策和物流方面的影響。

嚴謹且多方面的調查方法，結合專家訪談、技術文獻和相關人員檢驗，確保了可靠且可操作的見解。

本研究途徑整合了定性專家訪談、技術文獻彙編以及與研發、生產和採購等相關相關人員的直接對話，從而對無血清培養基的現狀提供多角度的觀點。資料收集包括與配方科學家、製程開發經理和採購專家進行結構化訪談，以及查閱同行評審文章、監管指南和企業資訊披露，以闡明產品特性和驗證途徑。

全面概述了無血清培養基在現代細胞培養和生物製藥開發中作為策略性、穩健且應用主導部分的地位。

總之，無血清培養基正從一項技術基礎發展成為一項策略性資產，影響研發速度、產品品質和生產穩定性。細胞生物學和分析技術的進步使得更精細的配方成為可能，以滿足哺乳動物和非哺乳動物系統的多樣化需求。同時，配方和產品類型的選擇旨在平衡操作便利性和法規的清晰度。監管要求和區域生產能力的差異正在影響無血清培養基的推廣應用，而不斷變化的貿易政策則促使企業考慮加強供應鏈並在適當情況下實現本地化生產。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：無血清培養基市場：依產品類型分類

  • 自訂培養基
  • 預定義培養基

第9章：無血清培養基市場－以無血清培養基類型分類

  • 化學成分明確的培養基（CDM）
  • 通用無血清培養基（SFM）
  • 非動物源性（NAO）培養基
  • 無蛋白培養基（PFM）
  • 不含異質成分的培養基

第10章 依細胞類型分類的無血清培養基市場

  • 哺乳動物細胞
    • CHO細胞
      • CHO-DG44
      • CHO-DXB11
      • CHO-K1
    • HEK293
    • NS0細胞
    • Vero細胞
  • 非哺乳動物細胞
    • 昆蟲細胞
    • 酵母菌細胞

第11章 無血清培養基的市場劑型

  • 液體類型
  • 粉末型

第12章：無血清培養基市場：依應用領域分類

  • 學術研究
    • 基因編輯
    • 幹細胞研究
  • 生物製藥生產
    • 單株抗體
    • 重組蛋白
    • 疫苗
  • 細胞和基因治療
    • CAR-T療法
    • 幹細胞療法
  • 組織工程與再生醫學

第13章 無血清培養基市場：依最終用戶分類

  • 生技公司
  • 合約研究機構
  • 製藥公司

第14章 無血清培養基市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 無血清培養基市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 無血清培養基市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國無血清培養基市場

第18章：中國無血清培養基市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Ajinomoto Co., Inc.
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Corning Incorporated
  • Danahar Corporation
  • FUJIFILM Holdings Corporation
  • Lonza Group AG
  • Merck KGaA
  • MP Biomedicals, LLC
  • Sartorius AG
  • STEMCELL Technologies Canada Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-7C31448F0BA9

The Serum-Free Media Market was valued at USD 2.51 billion in 2024 and is projected to grow to USD 2.76 billion in 2025, with a CAGR of 10.07%, reaching USD 4.47 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.51 billion
Estimated Year [2025] USD 2.76 billion
Forecast Year [2030] USD 4.47 billion
CAGR (%) 10.07%

An insightful introduction that frames serum-free media as a cornerstone enabling reproducible cell culture, scalable bioprocessing, and safer biologics development

The serum-free media landscape is evolving rapidly as scientific advances, regulatory expectations, and commercial imperatives converge to reshape how cell culture is performed across research and production environments. Serum-free formulations have transitioned from niche technical solutions to foundational enabling technologies that reduce variability, mitigate biological risks, and streamline downstream processing. Industry stakeholders are prioritizing defined inputs, reproducible performance, and compatibility with scalable bioprocessing workflows in order to support higher-complexity biologics, cell and gene therapies, and regenerative medicine applications.

Technological progress in media chemistry, analytical characterization, and cell biology has expanded the functional footprint of serum-free solutions. This progress is underpinned by increased understanding of cell-specific nutrient requirements, novel supplement strategies that replace poorly defined serum components, and a stronger emphasis on quality control across raw materials. Consequently, organizations that align formulation design with cell biology and manufacturing constraints can improve process consistency and reduce regulatory friction. As a result, serum-free media are now evaluated not only for biological performance but also for supply-chain robustness and compatibility with single-use systems, automation, and closed processing to meet contemporary production needs.

How scientific advancements, regulatory scrutiny, and industrialization of cell therapies are reshaping serum-free media into a strategic bioprocess enabler

The landscape for serum-free media is undergoing transformative shifts driven by scientific innovation, industrialization of cell therapies, and heightened regulatory attention to raw material traceability. Advances in cell-line engineering and systems biology have increased demand for formulations tailored to specific cellular phenotypes, moving away from one-size-fits-all recipes toward bespoke media that optimize productivity and critical quality attributes. Concurrently, the industrialization of cell and gene therapies has created pressure for media that perform robustly at scale while supporting regulatory dossiers that require consistent, well-characterized inputs.

In addition, sustainability and supply-chain resilience are rising priorities. Manufacturers are targeting reduction of animal-derived components to address ethical concerns and reduce variability, while procurement teams are adopting multi-sourcing strategies to guard against disruptions. Analytical innovations, including improved metabolite profiling and real-time process monitoring, enable more precise formulation tuning and faster troubleshooting of process drift. Taken together, these shifts are accelerating the maturation of serum-free media from a specialized reagent into a strategic component of bioprocess platforms that supports reproducibility, regulatory compliance, and operational scalability.

Evaluating the downstream supply chain and operational resilience consequences stemming from tariff-driven disruptions affecting serum-free media inputs and logistics

The cumulative impact of tariff policies announced for 2025 has introduced new complexity into supply chains for raw materials and finished serum-free formulations. Tariff measures affecting reagents, amino acids, specialized growth factors, and packaging components have the potential to increase landed costs and extend lead times for critical inputs. In response, procurement and supply chain teams are prioritizing inventory strategies, alternative sourcing, and supplier qualification activities to maintain continuity of supply while preserving product quality and compliance.

Beyond immediate cost pressures, tariffs influence strategic location decisions for manufacturing and fill-finish operations. Some organizations are reassessing regional sourcing hubs and considering nearshoring to reduce exposure to tariff volatility and transport disruptions. Regulatory compliance considerations remain paramount, as any supply-chain realignment must preserve documentation for traceability and change control. As a consequence, companies are investing in enhanced supplier audits, dual-sourcing where feasible, and tighter contractual protections to manage risk. Collectively, these responses underscore a broader trend toward resilient supply architectures designed to absorb policy-driven shocks while maintaining the performance and safety that end-users expect.

Comprehensive segmentation insights revealing how cell type, product architecture, formulation choices, application demands, and end-user needs shape formulation strategies

Segmentation provides a structured lens to interpret where technical demand and commercial opportunity intersect within the serum-free media ecosystem. Based on cell type, distinctions between Mammalian Cells and Non-Mammalian Cells are central to formulation design because nutrient utilization, growth kinetics, and product quality attributes differ markedly. Mammalian Cells, including CHO Cells, HEK293, NS0 Cells, and Vero Cells, present diverse requirements for osmolality, growth factors, and supplements that influence productivity and post-translational modifications. Non-Mammalian Cells, exemplified by Insect Cells and Yeast Cells, impose different metabolic demands and tolerance profiles, often enabling cost efficiencies but requiring alternative buffering and carbon source strategies.

Based on product type, differentiation between Custom Media and Defined Media drives procurement and R&D priorities. Custom Media solutions are tailored for specific cell lines or product goals and often require deeper analytical support and iterative optimization, whereas Defined Media prioritize reproducibility and regulatory clarity by minimizing undefined components. Based on formulation, choices between Liquid Form and Powdered Form have operational implications: liquid formats deliver convenience and reduced reconstitution variability but involve higher transport volumes and cold-chain considerations, while powdered formats offer storage and logistics advantages alongside on-site reconstitution needs.

Based on application, academic research, biopharmaceutical production, cell & gene therapy, and tissue engineering each demand unique performance attributes. Academic Research applications, including Gene Editing and Stem Cell Research, value flexibility and experimental reproducibility. Biopharmaceutical Production subsegments-Monoclonal Antibodies, Recombinant Proteins, and Vaccines-prioritize process consistency, scalability, and regulatory documentation. Cell & Gene Therapy areas such as CAR-T Therapy and Stem Cell Therapy require media that support cell viability, functionality, and safety in clinical manufacturing. Finally, based on end user, requirements differ across Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, with each class placing distinct emphasis on speed-to-data, regulatory readiness, and scalable supply.

Regional dynamics and regulatory landscapes that determine adoption patterns, supply-chain strategies, and development priorities across global regions

Regional dynamics significantly influence how serum-free media are developed, produced, and adopted across different ecosystems. The Americas exhibit strong integration between academic innovation hubs, contract development and manufacturing organizations, and large-scale biopharmaceutical production facilities, which together drive demand for formulations that are compatible with GMP environments and scalable manufacturing workflows. Regulatory systems and established supply-chain networks in this region also support rapid translation from lab to clinic.

Europe, Middle East & Africa blends stringent regulatory oversight with a diverse supplier base and growing investment in advanced therapies. In this region, emphasis on traceability, ethical sourcing, and compliance with complex regulatory frameworks encourages adoption of highly characterized, defined formulations. The need for harmonized documentation and environmental sustainability considerations also shapes procurement decisions.

Asia-Pacific combines accelerating biopharmaceutical development with manufacturing capacity expansion and rapidly evolving regulatory frameworks. Local demand for cost-effective and high-performance media is rising in parallel with investments in indigenous cell therapy programs and vaccine production. Moreover, partnerships between multinational firms and regional manufacturers are influencing formulation availability and local qualification processes. Across all regions, strategic considerations such as supply-chain localization, regulatory harmonization, and talent development remain central to successful deployment of serum-free solutions.

Competitive and corporate strategies shaping product innovation, partnerships, and quality-driven differentiation in the serum-free media ecosystem

Competitive dynamics in the serum-free media space are shaped by companies that combine formulation expertise, regulatory know-how, and supply-chain capabilities. Leading organizations are investing in application-specific media, launching products that target high-value therapeutic segments, and expanding analytical services to support customer qualification. Strategic partnerships with contract development and manufacturing organizations and academic centers of excellence are common, enabling faster validation and route-to-market for specialized formulations.

Innovation pathways include modular product architectures that enable rapid customization, licensing models that facilitate co-development, and service offerings that bundle technical support, method transfer, and stability data. In parallel, manufacturers are placing emphasis on raw material traceability and supplier transparency to meet the heightened expectations of regulatory agencies and forward-looking customers. Companies that integrate robust quality management systems with agile commercial and technical support functions are positioned to win in environments where performance, documentation, and continuity of supply converge as decisive buyer criteria.

Practical recommendations for R&D, supply chain, regulatory, and commercial leaders to build resilience, accelerate adoption, and improve product-market fit

To capture strategic value, industry leaders should adopt a set of coordinated actions that align R&D, supply chain, and commercial functions. First, prioritize investments in analytical platforms and cell-specific formulation science to accelerate development cycles and reduce risk during scale-up. Equally important is the development of flexible manufacturing strategies that include dual sourcing for critical inputs and options for regional production to mitigate policy and logistics disruptions.

Next, reinforce regulatory and quality frameworks by documenting raw material provenance, implementing comprehensive supplier qualification programs, and maintaining robust change control processes to expedite regulatory submissions. From a commercial perspective, offer tiered product and service packages that address the distinct needs of academic labs, CDMOs, and pharmaceutical manufacturers, thereby improving customer retention and enabling premium service offerings. Finally, foster collaborative ecosystems with academic centers and clinical partners to validate formulations in relevant applications, create shared data assets, and accelerate adoption across translational pathways. Together, these measures increase resilience, improve product-market fit, and support sustainable growth.

A rigorous, multi-source research methodology combining expert interviews, technical literature, and stakeholder validation to ensure reliable and actionable insights

The research approach integrates qualitative expert interviews, technical literature synthesis, and primary engagement with stakeholders across R&D, manufacturing, and procurement to produce a nuanced perspective on the serum-free media landscape. Data collection included structured conversations with formulation scientists, process development leaders, and procurement specialists, complemented by review of peer-reviewed publications, regulatory guidance, and company disclosures that clarify product attributes and validation pathways.

Analytical methods emphasized triangulation to ensure findings reflect operational realities: cross-validation of technical performance claims with independent laboratory reports, comparison of supplier capabilities against documented quality systems, and mapping of application requirements to formulation characteristics. For segmentation and regional analysis, the methodology relied on direct input from end users and service providers to identify demand drivers and operational constraints. Throughout, the research adhered to rigorous standards for source attribution, methodological transparency, and reproducibility so readers can evaluate the alignment of insights with their own data and priorities.

Concluding synthesis that emphasizes serum-free media as a strategic, resilient, and application-driven component of modern cell culture and biologics development

In summary, serum-free media are transitioning from technical enablers to strategic assets that influence development speed, product quality, and manufacturing resilience. Scientific advances in cell biology and analytics are enabling more tailored formulations that meet the diverse needs of mammalian and non-mammalian systems, while formulation formats and product types are being selected to balance operational convenience with regulatory clarity. Regional differences in regulatory expectations and manufacturing capacity shape adoption trajectories, and evolving trade policies are prompting companies to shore up supply chains and consider localization where appropriate.

Moving forward, organizations that invest in application-specific R&D, strengthen supplier transparency, and align commercial models to end-user needs will be best positioned to deliver value. Integration of high-quality analytical data with collaborative partnerships will accelerate qualification and adoption, and careful attention to operational resilience will mitigate the impact of policy and logistics disruptions. Collectively, these elements point to a future where serum-free media are integral to reproducible science and scalable biologics manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Serum-Free Media Market, by Product Type

  • 8.1. Custom Media
  • 8.2. Defined Media

9. Serum-Free Media Market, by Serum-Free Media Type

  • 9.1. Chemically Defined Media (CDM)
  • 9.2. Common Serum-Free Media (SFM)
  • 9.3. Non-Animal Origin (NAO) Media
  • 9.4. Protein-Free Media (PFM)
  • 9.5. Xeno-Free Media

10. Serum-Free Media Market, by Cell Type

  • 10.1. Mammalian Cells
    • 10.1.1. CHO Cells
      • 10.1.1.1. CHO-DG44
      • 10.1.1.2. CHO-DXB11
      • 10.1.1.3. CHO-K1
    • 10.1.2. HEK293
    • 10.1.3. NS0 Cells
    • 10.1.4. Vero Cells
  • 10.2. Non-Mammalian Cells
    • 10.2.1. Insect Cells
    • 10.2.2. Yeast Cells

11. Serum-Free Media Market, by Formulation

  • 11.1. Liquid Form
  • 11.2. Powdered Form

12. Serum-Free Media Market, by Application

  • 12.1. Academic Research
    • 12.1.1. Gene Editing
    • 12.1.2. Stem Cell Research
  • 12.2. Biopharmaceutical Production
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Recombinant Proteins
    • 12.2.3. Vaccines
  • 12.3. Cell & Gene Therapy
    • 12.3.1. CAR-T Therapy
    • 12.3.2. Stem Cell Therapy
  • 12.4. Tissue Engineering & Regenerative Medicine

13. Serum-Free Media Market, by End User

  • 13.1. Biotechnology Companies
  • 13.2. Contract Research Organizations
  • 13.3. Pharmaceutical Companies

14. Serum-Free Media Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Serum-Free Media Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Serum-Free Media Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Serum-Free Media Market

18. China Serum-Free Media Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Ajinomoto Co., Inc.
  • 19.6. Becton, Dickinson and Company
  • 19.7. Bio-Techne Corporation
  • 19.8. Corning Incorporated
  • 19.9. Danahar Corporation
  • 19.10. FUJIFILM Holdings Corporation
  • 19.11. Lonza Group AG
  • 19.12. Merck KGaA
  • 19.13. MP Biomedicals, LLC
  • 19.14. Sartorius AG
  • 19.15. STEMCELL Technologies Canada Inc.
  • 19.16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL SERUM-FREE MEDIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL SERUM-FREE MEDIA MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 114. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 117. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 118. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 122. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 123. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 124. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 125. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 127. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 128. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 135. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 136. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 137. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 138. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 140. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 141. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 148. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 149. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 150. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 151. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 153. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 154. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 183. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 187. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 188. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 189. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 192. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 193. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 196. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 200. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 201. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 202. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 203. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 205. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 206. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 227. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 228. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 229. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 230. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 232. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 233. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. GCC SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 236. GCC SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GCC SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. GCC SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. GCC SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 240. GCC SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 241. GCC SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 242. GCC SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 243. GCC SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. GCC SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 245. GCC SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 246. GCC SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. GCC SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 259. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. BRICS SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 262. BRICS SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. BRICS SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. BRICS SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. BRICS SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 266. BRICS SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 267. BRICS SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 268. BRICS SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 269. BRICS SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. BRICS SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 271. BRICS SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 272. BRICS SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 273. BRICS SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. G7 SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 275. G7 SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. G7 SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. G7 SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. G7 SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 279. G7 SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 280. G7 SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 281. G7 SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 282. G7 SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. G7 SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 284. G7 SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 285. G7 SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. G7 SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. NATO SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 288. NATO SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. NATO SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NATO SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. NATO SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 292. NATO SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 293. NATO SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 294. NATO SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. NATO SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 296. NATO SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 297. NATO SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 298. NATO SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. NATO SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 300. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 301. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 302. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 306. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 307. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 308. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 309. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. CHINA SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 315. CHINA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. CHINA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. CHINA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. CHINA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 319. CHINA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 320. CHINA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 321. CHINA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 322. CHINA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 323. CHINA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 324. CHINA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 325. CHINA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 326. CHINA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)